♥
ISIN : INE268B01013
NSE : KREBSBIO
BSE : 524518
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : -9.16
EPS (TTM) : -9.09
Price to Earning (P/E) : -7.25
Book Value : -55.29
Price to Bookvalue (P/B) : -1.20
Dividend Yield : 0 %
Return on Equity (ROE) : %
Return on Capital Employed (ROCE) : -18.99 %
Krebs Biochemicals and Industries Limited
ISIN : INE268B01013
NSE : KREBSBIO
BSE : 524518
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : -9.16
EPS (TTM) : -9.09
Price to Earning (P/E) : -7.25
Book Value : -55.29
Price to Bookvalue (P/B) : -1.20
Dividend Yield : 0 %
Return on Equity (ROE) : %
Return on Capital Employed (ROCE) : -18.99 %
Krebs Biochemicals share price(02-Apr-2026) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 45.5 - 45.6 0.2 % |
| Low / High | 42.86 - 47.88 11.7 % |
| Trade Volume | 2,116 |
| 52 Week Low / High | 38.52 - 113.9 195.7 % |
-
YOU MAY ALSO LIKE
- Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE - High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - Share Market basics for beginners
Share Market jargons in simple terms - How much money do you need to retire
Know how much money do you need to retire, before how much to invest ? - Stock market course tutorial
Stock Market Investment Course explained in simple words.
CONSOLIDATED QUARTERLY RESULT FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| Date End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 191.58 | 106.41 | 209.43 | 90.91 | 114.61 | 105.81 | 148.9 | 129.77 | 119.73 | 128.89 |
| Total Income | 199.51 | 107.7 | 212.17 | 91.14 | 116.54 | 106.19 | 150.64 | 130.07 | 121.83 | 129.22 |
| Total Expenditure | 289.36 | 169.09 | 228.44 | 120.78 | 160.85 | 132.01 | 157.91 | 150.67 | 150.87 | 150.85 |
| Other Income | 7.93 | 1.29 | 2.75 | 0.23 | 1.93 | 0.38 | 1.74 | 0.29 | 2.1 | 0.34 |
| Operating Profit | -89.85 | -61.39 | -16.27 | -29.64 | -44.31 | -25.82 | -7.27 | -20.6 | -29.04 | -21.63 |
| Interest | 2.8 | 3.04 | 7.42 | 8.98 | 10.28 | 10.97 | 11.34 | 11.86 | 12.72 | 13.18 |
| PBDT | -92.65 | -64.43 | -23.69 | -38.62 | -54.59 | -36.79 | -18.61 | -32.46 | -41.76 | -34.81 |
| Depreciation | 20.49 | 16.93 | 16.93 | 16.93 | 14.8 | 16.53 | 17.11 | 17.31 | 16.72 | 16.9 |
| Profit Before Tax | -113.14 | -81.36 | -40.62 | -55.55 | -69.39 | -53.32 | -35.72 | -49.77 | -58.48 | -51.71 |
| Profit After Tax | -113.14 | -81.36 | -40.62 | -55.55 | -69.39 | -53.32 | -35.72 | -49.77 | -58.48 | -51.71 |
| Net Profit | -113.14 | -81.36 | -40.62 | -55.55 | -69.39 | -53.32 | -35.72 | -49.77 | -58.48 | -51.71 |
| Equity Capital | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Calculated EPS | -5.25 | -3.77 | -1.88 | -2.58 | -3.22 | -2.47 | -1.66 | -2.31 | -2.71 | -2.4 |
| Diluted Eps After Extraordinary Items | -5.39 | -3.77 | -1.88 | -2.58 | -3.07 | -2.47 | -1.66 | -2.31 | -2.72 | -2.4 |
| Diluted Eps Before Extraordinary Items | -5.39 | -3.77 | -1.88 | -2.58 | -3.07 | -2.47 | -1.66 | -2.31 | -2.72 | -2.4 |
STANDALONE QUARTERLY RESULT FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| Date End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 191.58 | 106.41 | 209.43 | 90.91 | 114.61 | 105.81 | 148.9 | 129.77 | 119.73 | 128.89 |
| Total Income | 199.51 | 107.7 | 212.17 | 91.14 | 116.54 | 106.19 | 150.64 | 130.07 | 121.83 | 129.22 |
| Total Expenditure | 289.36 | 169.09 | 228.44 | 120.78 | 160.85 | 132.01 | 157.91 | 150.67 | 150.87 | 150.85 |
| Other Income | 7.93 | 1.29 | 2.75 | 0.23 | 1.93 | 0.38 | 1.74 | 0.29 | 2.1 | 0.34 |
| Operating Profit | -89.85 | -61.39 | -16.27 | -29.64 | -44.31 | -25.82 | -7.27 | -20.6 | -29.04 | -21.63 |
| Interest | 2.8 | 3.04 | 7.42 | 8.98 | 10.28 | 10.97 | 11.34 | 11.86 | 12.72 | 13.18 |
| PBDT | -92.65 | -64.43 | -23.69 | -38.62 | -54.59 | -36.79 | -18.61 | -32.46 | -41.76 | -34.81 |
| Depreciation | 20.49 | 16.93 | 16.93 | 16.93 | 14.8 | 16.53 | 17.11 | 17.31 | 16.72 | 16.9 |
| Profit Before Tax | -113.14 | -81.36 | -40.62 | -55.55 | -69.39 | -53.32 | -35.72 | -49.77 | -58.48 | -51.71 |
| Profit After Tax | -113.14 | -81.36 | -40.62 | -55.55 | -69.39 | -53.32 | -35.72 | -49.77 | -58.48 | -51.71 |
| Net Profit | -113.14 | -81.36 | -40.62 | -55.55 | -69.39 | -53.32 | -35.72 | -49.77 | -58.48 | -51.71 |
| Equity Capital | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 | 215.61 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Calculated EPS | -5.25 | -3.77 | -1.88 | -2.58 | -3.22 | -2.47 | -1.66 | -2.31 | -2.71 | -2.4 |
| Diluted Eps After Extraordinary Items | -5.39 | -3.77 | -1.88 | -2.58 | -3.07 | -2.47 | -1.66 | -2.31 | -2.72 | -2.4 |
| Diluted Eps Before Extraordinary Items | -5.39 | -3.77 | -1.88 | -2.58 | -3.07 | -2.47 | -1.66 | -2.31 | -2.72 | -2.4 |
CONSOLIDATED ANNUAL RESULT FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 597.03 | 521.34 | 504.22 |
| Total Income | 608.59 | 527.55 | 508.73 |
| Total Expenditure | 936.98 | 679.14 | 591.45 |
| Other Income | 11.56 | 6.2 | 4.51 |
| Operating Profit | -328.39 | -151.59 | -82.72 |
| Interest | 53.91 | 29.73 | 46.89 |
| PBDT | -382.3 | -181.32 | -129.61 |
| Depreciation | 62.97 | 65.59 | 67.66 |
| Profit Before Tax | -445.27 | -246.91 | -197.27 |
| Profit After Tax | -445.27 | -246.91 | -197.27 |
| Net Profit | -445.27 | -246.91 | -197.27 |
| Equity Capital | 215.61 | 215.61 | 215.61 |
| Face Value (IN RS) | 10 | 10 | 10 |
| Reserves | -1077.05 | -1320.74 | -1518.28 |
| Calculated EPS | -20.65 | -11.45 | -9.15 |
| Diluted Eps After Extraordinary Items | -20.81 | -11.3 | -9.16 |
| Diluted Eps Before Extraordinary Items | -20.81 | -11.3 | -9.16 |
STANDALONE ANNUAL RESULT FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 597.03 | 521.34 | 504.22 |
| Total Income | 608.59 | 527.55 | 508.73 |
| Total Expenditure | 936.98 | 679.14 | 591.45 |
| Other Income | 11.56 | 6.2 | 4.51 |
| Operating Profit | -328.39 | -151.59 | -82.72 |
| Interest | 53.91 | 29.73 | 46.89 |
| PBDT | -382.3 | -181.32 | -129.61 |
| Depreciation | 62.97 | 65.59 | 67.66 |
| Profit Before Tax | -445.27 | -246.91 | -197.27 |
| Profit After Tax | -445.27 | -246.91 | -197.27 |
| Net Profit | -445.27 | -246.91 | -197.27 |
| Equity Capital | 215.61 | 215.61 | 215.61 |
| Face Value (IN RS) | 10 | 10 | 10 |
| Reserves | -1077.05 | -1320.74 | -1518.28 |
| Calculated EPS | -20.65 | -11.45 | -9.15 |
| Diluted Eps After Extraordinary Items | -20.81 | -11.3 | -9.16 |
| Diluted Eps Before Extraordinary Items | -20.81 | -11.3 | -9.16 |
CONSOLIDATED PROFIT / LOSS FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 53.7 Cr | 59.7 Cr | 52.13 Cr | 50.42 Cr |
| Sales | 38.61 Cr | 52.94 Cr | 26.64 Cr | 6.51 Cr |
| Job Work/ Contract Receipts | 13.77 Cr | 5.44 Cr | 0 | 0 |
| Processing Charges / Service Income | 30.51 Lk | 30.51 Lk | 25.5 Cr | 43.91 Cr |
| Net Sales | 53.7 Cr | 59.7 Cr | 52.13 Cr | 50.42 Cr |
| Increase/Decrease in Stock | 32.49 Lk | -5.54 Cr | 5.87 Cr | 1.07 Cr |
| Raw Material Consumed | 25.62 Cr | 46.18 Cr | 19.81 Cr | 5.52 Cr |
| Opening Raw Materials | 6.52 Cr | 8.36 Cr | 10 Cr | 3.36 Cr |
| Purchases Raw Materials | 27.46 Cr | 47.82 Cr | 8.72 Cr | 4.75 Cr |
| Closing Raw Materials | 8.36 Cr | 10 Cr | 3.36 Cr | 2.67 Cr |
| Other Direct Purchases / Brought in cost | 0 | 0 | 4.44 Cr | 8.63 Lk |
| Power & Fuel Cost | 15.91 Cr | 22.79 Cr | 14.8 Cr | 22.01 Cr |
| Electricity & Power | 15.91 Cr | 22.79 Cr | 14.8 Cr | 22.01 Cr |
| Employee Cost | 15.3 Cr | 14.93 Cr | 15.54 Cr | 16.17 Cr |
| Salaries, Wages & Bonus | 14.51 Cr | 14.33 Cr | 15.1 Cr | 15.65 Cr |
| Workmen and Staff Welfare Expenses | 79.16 Lk | 60.1 Lk | 44.9 Lk | 52.64 Lk |
| Other Manufacturing Expenses | 10.37 Cr | 10.27 Cr | 8.48 Cr | 11.25 Cr |
| Processing Charges | 0 | 3.43 Cr | 3.25 Cr | 4.4 Cr |
| Repairs and Maintenance | 6.24 Cr | 5.53 Cr | 2.04 Cr | 2.81 Cr |
| General and Administration Expenses | 3.47 Cr | 4.6 Cr | 3.25 Cr | 3.03 Cr |
| Rent , Rates & Taxes | 70.72 Lk | 1.58 Cr | 87.88 Lk | 75.16 Lk |
| Insurance | 8.27 Lk | 10.94 Lk | 7.16 Lk | 9.58 Lk |
| Printing and stationery | 20.92 Lk | 24.85 Lk | 28.25 Lk | 30.41 Lk |
| Professional and legal fees | 29.64 Lk | 72.71 Lk | 45.34 Lk | 20.09 Lk |
| Traveling and conveyance | 43.81 Lk | 29.42 Lk | 4.54 Lk | 10.3 Lk |
| Selling and Distribution Expenses | 14.01 Lk | 23.42 Lk | 16.38 Lk | 9.03 Lk |
| Advertisement & Sales Promotion | 47,000 | 38,000 | 0 | 0 |
| Freight and Forwarding | 13.54 Lk | 23.04 Lk | 16.38 Lk | 9.03 Lk |
| Miscellaneous Expenses | 13.29 Lk | 18.12 Lk | 0 | 0 |
| Bad debts /advances written off | 8.02 Lk | 0 | 0 | 0 |
| Total Expenditure | 71.28 Cr | 93.64 Cr | 67.91 Cr | 59.15 Cr |
| Other Income | 62.13 Lk | 1.16 Cr | 62.01 Lk | 45.13 Lk |
| Interest Received | 7.21 Lk | 35.78 Lk | 12.69 Lk | 15.56 Lk |
| Operating Profit | -16.96 Cr | -32.78 Cr | -15.16 Cr | -8.27 Cr |
| Interest | 6.28 Cr | 5.45 Cr | 2.97 Cr | 4.69 Cr |
| Intereston Fixed deposits | 4.4 Cr | 4.51 Cr | 2.09 Cr | 3.87 Cr |
| Bank Charges etc | 73,000 | 64,000 | 22,000 | 35,000 |
| PBDT | -23.23 Cr | -38.23 Cr | -18.13 Cr | -12.96 Cr |
| Depreciation | 5.12 Cr | 6.3 Cr | 6.56 Cr | 6.77 Cr |
| Profit Before Taxation & Exceptional Items | -28.36 Cr | -44.53 Cr | -24.69 Cr | -19.73 Cr |
| Profit Before Tax | -28.36 Cr | -44.53 Cr | -24.69 Cr | -19.73 Cr |
| Profit After Tax | -28.36 Cr | -44.53 Cr | -24.69 Cr | -19.73 Cr |
| Other Consolidated Items | 0 | -34.65 Lk | 32.28 Lk | -2.6 Lk |
| Consolidated Net Profit | -28.36 Cr | -44.87 Cr | -24.37 Cr | -19.75 Cr |
| Profit Balance B/F | -153.06 Cr | -181.24 Cr | -226.12 Cr | -250.48 Cr |
| Appropriations | -181.42 Cr | -226.12 Cr | -250.48 Cr | -270.24 Cr |
| Other Appropriation | -17.27 Lk | 0 | 0 | 0 |
| Earnings Per Share | -14.45 | -20.65 | -11.45 | -9.15 |
| Adjusted EPS | -14.45 | -20.65 | -11.45 | -9.15 |
STANDALONE PROFIT / LOSS FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 53.7 Cr | 59.7 Cr | 52.13 Cr | 50.42 Cr |
| Sales | 38.61 Cr | 52.94 Cr | 26.64 Cr | 6.51 Cr |
| Job Work/ Contract Receipts | 13.77 Cr | 5.44 Cr | 0 | 0 |
| Processing Charges / Service Income | 30.51 Lk | 30.51 Lk | 25.5 Cr | 43.91 Cr |
| Net Sales | 53.7 Cr | 59.7 Cr | 52.13 Cr | 50.42 Cr |
| Increase/Decrease in Stock | 32.49 Lk | -5.54 Cr | 5.87 Cr | 1.07 Cr |
| Raw Material Consumed | 25.62 Cr | 46.18 Cr | 19.81 Cr | 5.52 Cr |
| Opening Raw Materials | 6.52 Cr | 8.36 Cr | 10 Cr | 3.36 Cr |
| Purchases Raw Materials | 27.46 Cr | 47.82 Cr | 8.72 Cr | 4.75 Cr |
| Closing Raw Materials | 8.36 Cr | 10 Cr | 3.36 Cr | 2.67 Cr |
| Other Direct Purchases / Brought in cost | 0 | 0 | 4.44 Cr | 8.63 Lk |
| Power & Fuel Cost | 15.91 Cr | 22.79 Cr | 14.8 Cr | 22.01 Cr |
| Electricity & Power | 15.91 Cr | 22.79 Cr | 14.8 Cr | 22.01 Cr |
| Employee Cost | 15.3 Cr | 14.93 Cr | 15.54 Cr | 16.17 Cr |
| Salaries, Wages & Bonus | 14.51 Cr | 14.33 Cr | 15.1 Cr | 15.65 Cr |
| Workmen and Staff Welfare Expenses | 79.16 Lk | 60.1 Lk | 44.9 Lk | 52.64 Lk |
| Other Manufacturing Expenses | 10.37 Cr | 10.27 Cr | 8.48 Cr | 11.25 Cr |
| Processing Charges | 0 | 3.43 Cr | 3.25 Cr | 4.4 Cr |
| Repairs and Maintenance | 6.24 Cr | 5.53 Cr | 2.04 Cr | 2.81 Cr |
| General and Administration Expenses | 3.47 Cr | 4.6 Cr | 3.25 Cr | 3.03 Cr |
| Rent , Rates & Taxes | 70.72 Lk | 1.58 Cr | 87.88 Lk | 75.16 Lk |
| Insurance | 8.27 Lk | 10.94 Lk | 7.16 Lk | 9.58 Lk |
| Printing and stationery | 20.92 Lk | 24.85 Lk | 28.25 Lk | 30.41 Lk |
| Professional and legal fees | 29.64 Lk | 72.71 Lk | 45.34 Lk | 20.09 Lk |
| Traveling and conveyance | 43.81 Lk | 29.42 Lk | 4.54 Lk | 10.3 Lk |
| Selling and Distribution Expenses | 14.01 Lk | 23.42 Lk | 16.38 Lk | 9.03 Lk |
| Advertisement & Sales Promotion | 47,000 | 38,000 | 0 | 0 |
| Freight and Forwarding | 13.54 Lk | 23.04 Lk | 16.38 Lk | 9.03 Lk |
| Miscellaneous Expenses | 13.29 Lk | 18.12 Lk | 0 | 0 |
| Bad debts /advances written off | 8.02 Lk | 0 | 0 | 0 |
| Total Expenditure | 71.28 Cr | 93.64 Cr | 67.91 Cr | 59.15 Cr |
| Other Income | 62.13 Lk | 1.16 Cr | 62.01 Lk | 45.13 Lk |
| Interest Received | 7.21 Lk | 35.78 Lk | 12.69 Lk | 15.56 Lk |
| Operating Profit | -16.96 Cr | -32.78 Cr | -15.16 Cr | -8.27 Cr |
| Interest | 6.28 Cr | 5.45 Cr | 2.97 Cr | 4.69 Cr |
| Intereston Fixed deposits | 4.4 Cr | 4.51 Cr | 2.09 Cr | 3.87 Cr |
| Bank Charges etc | 73,000 | 64,000 | 22,000 | 35,000 |
| PBDT | -23.23 Cr | -38.23 Cr | -18.13 Cr | -12.96 Cr |
| Depreciation | 5.12 Cr | 6.3 Cr | 6.56 Cr | 6.77 Cr |
| Profit Before Taxation & Exceptional Items | -28.36 Cr | -44.53 Cr | -24.69 Cr | -19.73 Cr |
| Profit Before Tax | -28.36 Cr | -44.53 Cr | -24.69 Cr | -19.73 Cr |
| Profit After Tax | -28.36 Cr | -44.53 Cr | -24.69 Cr | -19.73 Cr |
| Other Consolidated Items | 0 | -34.65 Lk | 32.28 Lk | -2.6 Lk |
| Consolidated Net Profit | -28.36 Cr | -44.87 Cr | -24.37 Cr | -19.75 Cr |
| Profit Balance B/F | -153.06 Cr | -181.24 Cr | -226.12 Cr | -250.48 Cr |
| Appropriations | -181.42 Cr | -226.12 Cr | -250.48 Cr | -270.24 Cr |
| Other Appropriation | -17.27 Lk | 0 | 0 | 0 |
| Earnings Per Share | -14.45 | -20.65 | -11.45 | -9.15 |
| Adjusted EPS | -14.45 | -20.65 | -11.45 | -9.15 |
CONSOLIDATED CASH FLOW FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | -28.36 Cr | -44.53 Cr | -24.69 Cr | -19.73 Cr |
| Adjustment | 11.68 Cr | 11.41 Cr | 9.82 Cr | 11.88 Cr |
| Changes In working Capital | 2.11 Cr | 15.9 Cr | -9.84 Cr | 10.15 Cr |
| Cash Flow after changes in Working Capital | -14.57 Cr | -17.22 Cr | -24.71 Cr | 2.3 Cr |
| Cash Flow from Operating Activities | -14.57 Cr | -17.22 Cr | -24.71 Cr | 2.3 Cr |
| Cash Flow from Investing Activities | -22.55 Cr | -22.9 Cr | -12.64 Cr | -7.82 Cr |
| Cash Flow from Financing Activitie | 37.66 Cr | 39.51 Cr | 37.34 Cr | 5.56 Cr |
| Net Cash Inflow / Outflow | 53.64 Lk | -61.01 Lk | -1.48 Lk | 5.14 Lk |
| Opening Cash & Cash Equivalents | 17.43 Lk | 71.07 Lk | 10.06 Lk | 8.58 Lk |
| Closing Cash & Cash Equivalent | 71.07 Lk | 10.06 Lk | 8.58 Lk | 13.72 Lk |
STANDALONE CASH FLOW FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | -28.36 Cr | -44.53 Cr | -24.69 Cr | -19.73 Cr |
| Adjustment | 11.68 Cr | 11.41 Cr | 9.82 Cr | 11.88 Cr |
| Changes In working Capital | 2.11 Cr | 15.9 Cr | -9.84 Cr | 10.15 Cr |
| Cash Flow after changes in Working Capital | -14.57 Cr | -17.22 Cr | -24.71 Cr | 2.3 Cr |
| Cash Flow from Operating Activities | -14.57 Cr | -17.22 Cr | -24.71 Cr | 2.3 Cr |
| Cash Flow from Investing Activities | -22.55 Cr | -22.9 Cr | -12.64 Cr | -7.82 Cr |
| Cash Flow from Financing Activitie | 37.66 Cr | 39.51 Cr | 37.34 Cr | 5.56 Cr |
| Net Cash Inflow / Outflow | 53.64 Lk | -61.01 Lk | -1.48 Lk | 5.14 Lk |
| Opening Cash & Cash Equivalents | 17.43 Lk | 71.07 Lk | 10.06 Lk | 8.58 Lk |
| Closing Cash & Cash Equivalent | 71.07 Lk | 10.06 Lk | 8.58 Lk | 13.72 Lk |
CONSOLIDATED BALANCE SHEET FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 19.62 Cr | 21.56 Cr | 21.56 Cr | 21.56 Cr |
| Equity - Authorised | 23 Cr | 23 Cr | 23 Cr | 23 Cr |
| Equity - Issued | 19.62 Cr | 21.56 Cr | 21.56 Cr | 21.56 Cr |
| Equity Paid Up | 19.62 Cr | 21.56 Cr | 21.56 Cr | 21.56 Cr |
| Face Value | 10 | 10 | 10 | 10 |
| Total Reserves | -66.52 Cr | -96.65 Cr | -121.02 Cr | -140.78 Cr |
| Securities Premium | 103.27 Cr | 118.02 Cr | 118.02 Cr | 118.02 Cr |
| Profit & Loss Account Balance | -181.24 Cr | -226.12 Cr | -250.48 Cr | -270.24 Cr |
| Reserve excluding Revaluation Reserve | -66.52 Cr | -96.65 Cr | -121.02 Cr | -140.78 Cr |
| Shareholder's Funds | -42.73 Cr | -75.09 Cr | -99.46 Cr | -119.22 Cr |
| Unsecured Loans | 100.55 Cr | 132.93 Cr | 173.25 Cr | 183.5 Cr |
| Loans - Govt. | 1.11 Cr | 56.32 Lk | 38 Lk | 24.65 Lk |
| Loans - Others | 3.55 Cr | 55 Lk | 0 | 0 |
| Other Long Term Liabilities | 45 Cr | 45 Cr | 45 Cr | 45 Cr |
| Long Term Trade Payables | 5.65 Cr | 6.27 Cr | 4.5 Cr | 4.01 Cr |
| Long Term Provisions | 2.56 Cr | 2.63 Cr | 2.6 Cr | 3.05 Cr |
| Total Non-Current Liabilities | 153.76 Cr | 186.84 Cr | 225.34 Cr | 235.56 Cr |
| Trade Payables | 20.78 Cr | 37.91 Cr | 15.28 Cr | 18.97 Cr |
| Sundry Creditors | 20.78 Cr | 37.91 Cr | 15.28 Cr | 18.97 Cr |
| Other Current Liabilities | 25.92 Cr | 29.01 Cr | 22.57 Cr | 31.87 Cr |
| Advances received from customers | 5.51 Cr | 12.35 Cr | 0 | 16.84 Cr |
| Interest Accrued But Not Due | 0 | 8.18 Cr | 6.06 Cr | 9.54 Cr |
| Short Term Borrowings | 0 | 9.99 Cr | 9.99 Cr | 9.93 Cr |
| Short Term Provisions | 1.49 Cr | 1.17 Cr | 1.26 Cr | 1.06 Cr |
| Total Current Liabilities | 48.19 Cr | 78.06 Cr | 49.1 Cr | 61.83 Cr |
| Total Liabilities | 159.22 Cr | 189.81 Cr | 174.98 Cr | 178.18 Cr |
| Gross Block | 260.88 Cr | 287.95 Cr | 303.04 Cr | 312.46 Cr |
| Less: Accumulated Depreciation | 142.95 Cr | 149.24 Cr | 155.73 Cr | 162.5 Cr |
| Net Block | 117.93 Cr | 138.71 Cr | 147.31 Cr | 149.96 Cr |
| Capital Work in Progress | 10.09 Cr | 6.53 Cr | 2.24 Cr | 15.57 Lk |
| Long Term Loans & Advances | 7.71 Cr | 7 Cr | 7.52 Cr | 8.77 Cr |
| Other Non Current Assets | 23.15 Lk | 22.28 Lk | 0 | 0 |
| Total Non-Current Assets | 137.8 Cr | 154.31 Cr | 158.92 Cr | 160.73 Cr |
| Inventories | 16.6 Cr | 25.56 Cr | 11.95 Cr | 9.8 Cr |
| Raw Materials | 8.36 Cr | 10 Cr | 3.36 Cr | 2.67 Cr |
| Work-in Progress | 6.64 Cr | 11.92 Cr | 6.39 Cr | 5.12 Cr |
| Finished Goods | 1.39 Cr | 1.65 Cr | 1.31 Cr | 1.51 Cr |
| Stores and Spare | 20.95 Lk | 60.57 Lk | 10.07 Lk | 49.45 Lk |
| Sundry Debtors | 29.98 Lk | 87.65 Lk | 52.52 Lk | 1.9 Cr |
| Debtors Others | 29.98 Lk | 87.65 Lk | 52.52 Lk | 1.9 Cr |
| Cash and Bank | 71.07 Lk | 10.06 Lk | 8.59 Lk | 13.74 Lk |
| Cash in hand | 24,000 | 4,000 | 25,000 | 10,000 |
| Balances at Bank | 70.83 Lk | 10.02 Lk | 8.34 Lk | 13.64 Lk |
| Other Current Assets | 47.2 Lk | 58.94 Lk | 65.39 Lk | 54.31 Lk |
| Interest accrued and or due on loans | 7.66 Lk | 9.69 Lk | 13.6 Lk | 16.71 Lk |
| Prepaid Expenses | 39.54 Lk | 49.25 Lk | 51.79 Lk | 37.6 Lk |
| Short Term Loans and Advances | 3.33 Cr | 8.36 Cr | 2.85 Cr | 5.06 Cr |
| Advances recoverable in cash or in kind | 58.02 Lk | 41.61 Lk | 56.05 Lk | 3.29 Cr |
| Total Current Assets | 21.42 Cr | 35.49 Cr | 16.06 Cr | 17.44 Cr |
| Net Current Assets (Including Current Investments) | -26.77 Cr | -42.57 Cr | -33.04 Cr | -44.39 Cr |
| Total Assets | 159.22 Cr | 189.81 Cr | 174.98 Cr | 178.18 Cr |
| Contingent Liabilities | 5.35 Cr | 5.55 Cr | 5.55 Cr | 9.94 Cr |
| Total Debt | 101.14 Cr | 143.1 Cr | 183.37 Cr | 193.68 Cr |
| Book Value | -23.91 | -34.83 | -46.13 | -55.29 |
| Adjusted Book Value | -23.91 | -34.83 | -46.13 | -55.29 |
STANDALONE BALANCE SHEET FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 19.62 Cr | 21.56 Cr | 21.56 Cr | 21.56 Cr |
| Equity - Authorised | 23 Cr | 23 Cr | 23 Cr | 23 Cr |
| Equity - Issued | 19.62 Cr | 21.56 Cr | 21.56 Cr | 21.56 Cr |
| Equity Paid Up | 19.62 Cr | 21.56 Cr | 21.56 Cr | 21.56 Cr |
| Face Value | 10 | 10 | 10 | 10 |
| Total Reserves | -66.52 Cr | -96.65 Cr | -121.02 Cr | -140.78 Cr |
| Securities Premium | 103.27 Cr | 118.02 Cr | 118.02 Cr | 118.02 Cr |
| Profit & Loss Account Balance | -181.24 Cr | -226.12 Cr | -250.48 Cr | -270.24 Cr |
| Reserve excluding Revaluation Reserve | -66.52 Cr | -96.65 Cr | -121.02 Cr | -140.78 Cr |
| Shareholder's Funds | -42.73 Cr | -75.09 Cr | -99.46 Cr | -119.22 Cr |
| Unsecured Loans | 100.55 Cr | 132.93 Cr | 173.25 Cr | 183.5 Cr |
| Loans - Govt. | 1.11 Cr | 56.32 Lk | 38 Lk | 24.65 Lk |
| Loans - Others | 3.55 Cr | 55 Lk | 0 | 0 |
| Other Long Term Liabilities | 45 Cr | 45 Cr | 45 Cr | 45 Cr |
| Long Term Trade Payables | 5.65 Cr | 6.27 Cr | 4.5 Cr | 4.01 Cr |
| Long Term Provisions | 2.56 Cr | 2.63 Cr | 2.6 Cr | 3.05 Cr |
| Total Non-Current Liabilities | 153.76 Cr | 186.84 Cr | 225.34 Cr | 235.56 Cr |
| Trade Payables | 20.78 Cr | 37.91 Cr | 15.28 Cr | 18.97 Cr |
| Sundry Creditors | 20.78 Cr | 37.91 Cr | 15.28 Cr | 18.97 Cr |
| Other Current Liabilities | 25.92 Cr | 29.01 Cr | 22.57 Cr | 31.87 Cr |
| Advances received from customers | 5.51 Cr | 12.35 Cr | 0 | 16.84 Cr |
| Interest Accrued But Not Due | 0 | 8.18 Cr | 6.06 Cr | 9.54 Cr |
| Short Term Borrowings | 0 | 9.99 Cr | 9.99 Cr | 9.93 Cr |
| Short Term Provisions | 1.49 Cr | 1.17 Cr | 1.26 Cr | 1.06 Cr |
| Total Current Liabilities | 48.19 Cr | 78.06 Cr | 49.1 Cr | 61.83 Cr |
| Total Liabilities | 159.22 Cr | 189.81 Cr | 174.98 Cr | 178.18 Cr |
| Gross Block | 260.88 Cr | 287.95 Cr | 303.04 Cr | 312.46 Cr |
| Less: Accumulated Depreciation | 142.95 Cr | 149.24 Cr | 155.73 Cr | 162.5 Cr |
| Net Block | 117.93 Cr | 138.71 Cr | 147.31 Cr | 149.96 Cr |
| Capital Work in Progress | 10.09 Cr | 6.53 Cr | 2.24 Cr | 15.57 Lk |
| Long Term Loans & Advances | 7.71 Cr | 7 Cr | 7.52 Cr | 8.77 Cr |
| Other Non Current Assets | 23.15 Lk | 22.28 Lk | 0 | 0 |
| Total Non-Current Assets | 137.8 Cr | 154.31 Cr | 158.92 Cr | 160.73 Cr |
| Inventories | 16.6 Cr | 25.56 Cr | 11.95 Cr | 9.8 Cr |
| Raw Materials | 8.36 Cr | 10 Cr | 3.36 Cr | 2.67 Cr |
| Work-in Progress | 6.64 Cr | 11.92 Cr | 6.39 Cr | 5.12 Cr |
| Finished Goods | 1.39 Cr | 1.65 Cr | 1.31 Cr | 1.51 Cr |
| Stores and Spare | 20.95 Lk | 60.57 Lk | 10.07 Lk | 49.45 Lk |
| Sundry Debtors | 29.98 Lk | 87.65 Lk | 52.52 Lk | 1.9 Cr |
| Debtors Others | 29.98 Lk | 87.65 Lk | 52.52 Lk | 1.9 Cr |
| Cash and Bank | 71.07 Lk | 10.06 Lk | 8.59 Lk | 13.74 Lk |
| Cash in hand | 24,000 | 4,000 | 25,000 | 10,000 |
| Balances at Bank | 70.83 Lk | 10.02 Lk | 8.34 Lk | 13.64 Lk |
| Other Current Assets | 47.2 Lk | 58.94 Lk | 65.39 Lk | 54.31 Lk |
| Interest accrued and or due on loans | 7.66 Lk | 9.69 Lk | 13.6 Lk | 16.71 Lk |
| Prepaid Expenses | 39.54 Lk | 49.25 Lk | 51.79 Lk | 37.6 Lk |
| Short Term Loans and Advances | 3.33 Cr | 8.36 Cr | 2.85 Cr | 5.06 Cr |
| Advances recoverable in cash or in kind | 58.02 Lk | 41.61 Lk | 56.05 Lk | 3.29 Cr |
| Total Current Assets | 21.42 Cr | 35.49 Cr | 16.06 Cr | 17.44 Cr |
| Net Current Assets (Including Current Investments) | -26.77 Cr | -42.57 Cr | -33.04 Cr | -44.39 Cr |
| Total Assets | 159.22 Cr | 189.81 Cr | 174.98 Cr | 178.18 Cr |
| Contingent Liabilities | 5.35 Cr | 5.55 Cr | 5.55 Cr | 9.94 Cr |
| Total Debt | 101.14 Cr | 143.1 Cr | 183.37 Cr | 193.68 Cr |
| Book Value | -23.91 | -34.83 | -46.13 | -55.29 |
| Adjusted Book Value | -23.91 | -34.83 | -46.13 | -55.29 |
FINANCIAL RATIOS (CONSOLIDATED) FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | -14.45 | -20.65 | -11.45 | -9.15 |
| CEPS(Rs) | -11.84 | -17.73 | -8.41 | -6.01 |
| Book NAV/Share(Rs) | -23.91 | -34.83 | -46.13 | -55.29 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | -32.73 | -56.84 | -30.27 | -17.3 |
| EBIT Margin(%) | -41.12 | -65.45 | -41.66 | -29.83 |
| Pre Tax Margin(%) | -52.81 | -74.58 | -47.36 | -39.13 |
| PAT Margin (%) | -52.81 | -74.58 | -47.36 | -39.13 |
| Cash Profit Margin (%) | -43.27 | -64.03 | -34.78 | -25.71 |
| Performance Ratios | ||||
| ROA(%) | -19.36 | -25.51 | -13.54 | -11.17 |
| ROCE(%) | -44.33 | -57.29 | -28.59 | -18.99 |
| Asset Turnover(x) | 0.37 | 0.34 | 0.29 | 0.29 |
| Sales/Fixed Asset(x) | 0.21 | 0.22 | 0.18 | 0.16 |
| Working Capital/Sales(x) | -2.01 | -1.4 | -1.58 | -1.14 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 4.69 | 4.6 | 5.67 | 6.1 |
| Receivable days | 1.71 | 3.6 | 4.91 | 8.79 |
| Inventory Days | 107.38 | 128.88 | 131.3 | 78.69 |
| Payable days | 108 | 263.51 | 378.02 | 948.9 |
| Valuation Parameters | ||||
| PCE(x) | -7.5 | -8.09 | -6.71 | -10.15 |
| Price/Book(x) | -3.72 | -4.12 | -1.22 | -1.1 |
| EV/Net Sales(x) | 5.12 | 7.57 | 5.85 | 6.45 |
| EV/Core EBITDA(x) | -16.2 | -13.79 | -20.11 | -39.3 |
| EV/EBIT(x) | -12.44 | -11.57 | -14.04 | -21.62 |
| EV/CE(x) | 1.73 | 2.38 | 1.74 | 4.37 |
| M Cap / Sales | 3.25 | 5.18 | 2.33 | 2.61 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 60.72 | 11.18 | -12.68 | -3.29 |
| Core EBITDA Growth(%) | 6.79 | -93.33 | 53.83 | 45.43 |
| EBIT Growth(%) | 3.45 | -76.99 | 44.5 | 30.76 |
| PAT Growth(%) | 1.78 | -57.01 | 44.55 | 20.1 |
| EPS Growth(%) | 9.89 | -42.89 | 44.55 | 20.1 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | -2.16 | -1.91 | -1.84 | -1.62 |
| Current Ratio(x) | 0.44 | 0.45 | 0.33 | 0.28 |
| Quick Ratio(x) | 0.1 | 0.13 | 0.08 | 0.12 |
| Interest Cover(x) | -3.52 | -7.17 | -7.3 | -3.21 |
| Total Debt/Mcap(x) | 0.58 | 0.46 | 1.51 | 1.47 |
FINANCIAL RATIOS (STANDALONE) FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | -14.45 | -20.65 | -11.45 | -9.15 |
| CEPS(Rs) | -11.84 | -17.73 | -8.41 | -6.01 |
| Book NAV/Share(Rs) | -23.91 | -34.83 | -46.13 | -55.29 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | -32.73 | -56.84 | -30.27 | -17.3 |
| EBIT Margin(%) | -41.12 | -65.45 | -41.66 | -29.83 |
| Pre Tax Margin(%) | -52.81 | -74.58 | -47.36 | -39.13 |
| PAT Margin (%) | -52.81 | -74.58 | -47.36 | -39.13 |
| Cash Profit Margin (%) | -43.27 | -64.03 | -34.78 | -25.71 |
| Performance Ratios | ||||
| ROA(%) | -19.36 | -25.51 | -13.54 | -11.17 |
| ROCE(%) | -44.33 | -57.29 | -28.59 | -18.99 |
| Asset Turnover(x) | 0.37 | 0.34 | 0.29 | 0.29 |
| Sales/Fixed Asset(x) | 0.21 | 0.22 | 0.18 | 0.16 |
| Working Capital/Sales(x) | -2.01 | -1.4 | -1.58 | -1.14 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 4.69 | 4.6 | 5.67 | 6.1 |
| Receivable days | 1.71 | 3.6 | 4.91 | 8.79 |
| Inventory Days | 107.38 | 128.88 | 131.3 | 78.69 |
| Payable days | 108 | 263.51 | 378.02 | 948.9 |
| Valuation Parameters | ||||
| PCE(x) | -7.5 | -8.09 | -6.71 | -10.15 |
| Price/Book(x) | -3.72 | -4.12 | -1.22 | -1.1 |
| EV/Net Sales(x) | 5.12 | 7.57 | 5.85 | 6.45 |
| EV/Core EBITDA(x) | -16.2 | -13.79 | -20.11 | -39.3 |
| EV/EBIT(x) | -12.44 | -11.57 | -14.04 | -21.62 |
| EV/CE(x) | 1.73 | 2.38 | 1.74 | 4.37 |
| M Cap / Sales | 3.25 | 5.18 | 2.33 | 2.61 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 60.72 | 11.18 | -12.68 | -3.29 |
| Core EBITDA Growth(%) | 6.79 | -93.33 | 53.83 | 45.43 |
| EBIT Growth(%) | 3.45 | -76.99 | 44.5 | 30.76 |
| PAT Growth(%) | 1.78 | -57.01 | 44.55 | 20.1 |
| EPS Growth(%) | 9.89 | -42.89 | 44.55 | 20.1 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | -2.16 | -1.91 | -1.84 | -1.62 |
| Current Ratio(x) | 0.44 | 0.45 | 0.33 | 0.28 |
| Quick Ratio(x) | 0.1 | 0.13 | 0.08 | 0.12 |
| Interest Cover(x) | -3.52 | -7.17 | -7.3 | -3.21 |
| Total Debt/Mcap(x) | 0.58 | 0.46 | 1.51 | 1.47 |
SHARE HOLDING PATTERN FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| Date | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters % | 72.74 | 72.74 | 72.72 | 72.74 | 72.74 | 72.74 | 72.74 | 72.74 | 72.74 | 72.74 |
| FII % | 0.01 | 0.00 | 0.32 | 0.49 | 0.49 | 0.49 | 0.49 | 0.49 | 0.49 | 0.49 |
| DII % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public % | 27.25 | 27.25 | 26.95 | 26.76 | 26.76 | 26.76 | 26.76 | 26.76 | 26.76 | 26.76 |
PEER COMPARISON FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
CORPORATE ACTIONS FOR KREBS BIOCHEMICALS
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 28-Oct-2024 | Board Meeting - Quarterly Results | 11-Nov-2024 |
| BSE 19-Jul-2024 | Board Meeting - Quarterly Results | 07-Aug-2024 |
| BSE 08-May-2024 | Board Meeting - Audited Results | 21-May-2024 |
| BSE 19-Jan-2024 | Board Meeting - Quarterly Results | 12-Feb-2024 |
| BSE 18-Oct-2023 | Board Meeting - Quarterly Results | 08-Nov-2023 |
| BSE 12-Sep-2023 | Book Closure - A.G.M. | 21-Sep-2023 27-Sep-2023 |
| BSE 12-Sep-2023 | AGM - A.G.M. | 27-Sep-2023 27-Sep-2023 |
| BSE 21-Jul-2023 | Board Meeting - Quarterly Results | 09-Aug-2023 |
| BSE 11-May-2023 | Board Meeting - Audited Results | 24-May-2023 |
| BSE 23-Jan-2023 | Board Meeting - Quarterly Results | 03-Feb-2023 |
| BSE 02-Nov-2022 | Board Meeting - Quarterly Results | 10-Nov-2022 |
| BSE 26-Jul-2022 | Board Meeting - Quarterly Results & Inter alia, to consider the following: 1. To consider and approve the un-audited financial results along with the Limited review Report for the quarter ended 30th June, 2022. 2. Any other matter with the permission of the Chair. | 01-Aug-2022 |
| BSE 13-May-2022 | Board Meeting - Audited Results | 23-May-2022 |
| BSE 07-Feb-2022 | Board Meeting - Quarterly Results | 12-Feb-2022 |
| BSE 02-Nov-2021 | Board Meeting - Quarterly Results | 09-Nov-2021 |
| BSE 18-Oct-2021 | Board Meeting - Preferential Issue of shares & Increase in Authorised Capital | 22-Oct-2021 |
| BSE 01-Sep-2021 | Book Closure - A.G.M. | 17-Sep-2021 23-Sep-2021 |
| BSE 01-Sep-2021 | AGM - A.G.M. | 23-Sep-2021 23-Sep-2021 |
CORPORATE ANNOUNCEMENTS FOR KREBS BIOCHEMICALS
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 28-Oct-2024 | Intimation FILE | Board Meeting Intimation for Intimation Of Board Meeting KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2024 inter alia to consider and approve Intimation of Board Meeting to be held on 11th November 2024 |
| BSE 04-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 The Company enclosing herewith copy of certificate under regulation 74 (5) of SEBI (DP) Regulations 2018 received from Kfintech Technologies Limited for the quarter ended 30.09.2024. |
| BSE 28-Sep-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report The company enclosed herewith scrutinizer report and voting results of 32nd Annual General Meeting held on 27th September 2024. |
| BSE 27-Sep-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Outcome of AGM The Company enclosed herewith proceedings of 32nd Annual General Meeting held on 27th September 2024. |
| BSE 23-Sep-2024 | Intimation FILE | Closure of Trading Window The trading window for dealing in securities of the Company will be remained closed w.e.f. close of business hours on 30th September 2024 untill 48 hours after declaration of unaudited financial results for the quarter and half year ended 30th September 2024 for promoter designated person and their immediate relatives and all connected persons. |
| BSE 04-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication The Company enclosed herewith notice published in the newspapers issued to shareholders with respect to Notice of 32nd AGM. |
| BSE 02-Sep-2024 | Intimation FILE | Notice Of 32Nd Annual General Meeting Of The Company The Company informed that the 32nd Annual General Meeting will be held on Friday 27th September 2024 at 11:30 am at the registered office of the company at Kothapalli (v) Kasimkota (M) Anakpalli(D) Vishakapatanam Andhra Pradesh.- 531031. |
| BSE 02-Sep-2024 | General Announcements FILE | Reg. 34 (1) Annual Report. The Company enclosed herewith copy of Annual Report for the financial year ended 31st March 2024. |
| BSE 30-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Reg 30 of the SEBI (LODR) Regulations 2015 we are enclosed herewith notice published in the newspapers in respect of prior intimation of 32nd Annual General Meeting. |
| BSE 08-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication The Company enclosed herewith copies of newspaper publication of financial results for quarter ended 30th June 2024 as published in newspapers. |
| BSE 07-Aug-2024 | Outcome FILE | Financial Results For The Quarter Ended 30.06.2024 Financial Results for the quarter ended 30.06.2024 |
| BSE 07-Aug-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of Board Meeting Held On 07.08.2024 Outcome of Board Meeting dated 07.08.2024 |
| BSE 19-Jul-2024 | Intimation FILE | Board Meeting Intimation for Intimation Of Board Meeting Under Reg 29 Of The SEBI (LODR) Regulations 2015 KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2024 inter alia to consider and approve The Company has informed that the meeting of Board of Directors of the Company is schedule on 07/08/2024 inter alia to consider and approve Unaudited Financial Results for the quarter ended 30th June 2024. |
| BSE 09-Jul-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 In compliances with Reg 74 (5) of SEBI (DP) Regulations we are enclosed herewith certificates received from RTA of the Company for the quarter ended 30.06.2024. |
| BSE 21-Jun-2024 | Intimation FILE | Closure of Trading Window Intimation for closure of trading window for the quarter ended 30th June 2024. |
| BSE 27-May-2024 | Compliance FILE | Compliances-Reg.24(A)-Annual Secretarial Compliance Secretarial Compliance Report for the year ended 31.03.2024 |
| BSE 22-May-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Copy of Newspaper Publication |
| BSE 21-May-2024 | General Announcements FILE | Appointment of Company Secretary and Compliance Officer Appointment of Company Secretary |
| BSE 21-May-2024 | Outcome FILE | Financial Results For The Year Ended 31.03.2024 Financial Results for the year ended 31.03.2024 |
| BSE 21-May-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of Board Meeting Outcome of Board Meeting dated 21.05.2024 |
| BSE 08-May-2024 | Intimation FILE | Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Will Be Held On Tuesday May 21 2024 Inter-Alia To Consider And Adopt The Audited Financial Results For The 4Th Quarter And Financial Year Ended 31St March 2024. KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 inter alia to consider and approve Audited Financial Results for the 4th quarter and financial year ended 31st March 2024. ` |
| BSE 22-Apr-2024 | Compliance FILE | Submission Of Certificate Under Reg. 40(9) Of SEBI (LODR) Regulations 2015 For The Year Ended 31.03.2024 Submission of certificate under Reg 40(9) of SEBI (LODR) Regulations 2015 for the year ended 31.03.2024. |
| BSE 15-Apr-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer Resignation of Mr. Keyur Doshi as Company Secretary and Compliance Officer of the Company. |
| BSE 08-Apr-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the Quarter ended 31st March 2024. |
| BSE 08-Apr-2024 | Compliance FILE | Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. Compliance Certificate under Regulation 7(3) of SEBI (LODR) Regulation 2015. |
| BSE 27-Mar-2024 | General Announcements FILE | Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015. Additional details in reference to our letter dated 20th October 2023 are enclosed herewith. |
| BSE 21-Mar-2024 | Intimation FILE | Closure of Trading Window Closure of Trading Window |
| BSE 13-Feb-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Unaudited Financial Results for 3rd Quarter and 9 Months ended 31 December 2023. |
| BSE 12-Feb-2024 | General Announcements FILE | Board Meeting Outcome For Outcome Of Board Meeting Held On 12 February 2024 Outcome of Board Meeting held on 12 February 2024. |
| BSE 12-Feb-2024 | Outcome FILE | Unaudited Financial Results Of The Company 3Rd Quarter And 9 Month Ended 31St December 2023. Please find enclosed herewith Unaudited Financial Results for 3rd Quarter and 9 Months ended 31st December 2023. |
INSIDER TRADING FOR KREBS BIOCHEMICALS
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Insider trading details found | |||
BULK BLOCK DEALS FOR KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Bulk Block details found | |||
DIVIDEND BY KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
No dividend details found
SPLIT / BONUS BY KREBS BIOCHEMICALS AND INDUSTRIES LIMITED
No Split / Bonus details found
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
